Bluebird bio — ASCO Analyst & Investor Webcast 2018
20 slides from Bluebird bio's conference presentation, Jun 4, 2018
Slide 1: ASCO Analyst & Investor Webcast
ASCO Analyst & Investor Webcast June 1, 2018 NASDAQ: BLUE June 1, 2018 Exhibit 99.1
Slide 2: Forward Looking Statements
These slides and the accompanying oral presentation contain forward-looking statements and information relating to bluebird bio, its product candidate bb2121 and oncology research and development plans. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “belie
Slide 3: Welcome
Welcome Nick Leschly, chief bluebird
Slide 4: bluemojo: Making Hope A Reality
~ bluemojo Making Hope A Reality
Slide 5: The Gene Therapy Company
T H E G E N E T H E R A P Y P R O D U C T S C O M P A N Y LentiGlobin SCD Data-Driven Acceleration LentiGlobin TDT First Filing (2018) Lenti-D CALD First Filing (2019) Patient Impact ∞ bb2121 Multiple Myeloma First Filing (2019) Products on the Market 2+ Additional Programs in the Clinic 4+ Programs
Slide 6: Key Questions for Today
Key Questions for Today What more have we learned about efficacy and durability of bb2121 in this heavily pretreated patient population? What are the new learnings? BCMA expression? Dose response? Is the safety profile still manageable? Is the path to earlier lines progressing?
Slide 7: CRB-401 Data Update
CRB-401 Data Update David Davidson, M.D., chief medical officer
Slide 8: Baseline Demographics and Clinical Characteristics
Baseline Demographics and Clinical Characteristics Parameter Escalation (N=21) Expansion (N=22) Median (min, max) follow-up, d 345 (46, 638) 87 (29, 184) Median (min, max) age, y 58 (37, 74) 65 (44, 75) Male, n (%) 13 (62) 16 (73) Median (min, max) time since diagnosis, y 4 (1, 16) 6 (1, 36) ECOG PS
Slide 9: Heavily Pretreated Patient Population
Parameter Escalation (N=21) Expansion (N=22) Exposed Refractory Exposed Refractory Prior therapies, n (%) Bortezomib 21 (100) 14 (67) 22 (100) 16 (73) Carfilzomib 19 (91) 12 (57) 21 (96) 14 (64) Lenalidomide 21 (100) 19 (91) 22 (100) 18 (82) Pomalidomide 19 (91) 15 (71) 22 (100) 21 (96) Daratumumab
Slide 10: Tumor Response: Dose-related and Independent of Myeloma BCMA Expression
CR, complete response; mDOR, median duration of response; ORR, objective response rate; PD, progressive disease; PR, partial response; sCR, stringent CR; VGPR, very good partial response. Data cut-off: March 29, 2018. 1Patients with ≥2 months of response data or PD/death within <2 months. ORR is def
Slide 11: Hitting the Mark for Progression Free Survival
Data cut-off: March 29, 2018. Median and 95% CI from Kaplan-Meier estimate. NE, not estimable. 1PFS in dose escalation cohort. mPFS of 11.8 months at active doses (≥150 x 106 CAR+ T cells) in 18 subjects in dose escalation mPFS of 17.7 months in 16 responding subjects from all study cohorts who are
Slide 12: CAR T Treatment-Emergent Adverse Events
TEAE, n (%) Overall Grade ≥3 Cytokine release syndrome1 27 (63) 2 (5) Neurotoxicity2 14 (33) 1 (2) Neutropenia 35 (81) 34 (79) Thrombocytopenia 26 (61) 22 (51) Anemia 24 (56) 19 (44) Infection3 Overall First Month 26 (61) 10 (23) 9 (21) 2 (5) CAR T Treatment-Emergent Adverse Events All Infused Patie
Slide 13: bb2121-MM-001: Registration-Enabling Trial (KarMMa)
Relapsed and refractory MM ≥3 prior treatment regimens with ≥ 2 consecutive cycles each (unless PD was best response) Received prior IMiD®, PI and anti-CD38 Refractory (per IMWG) to last treatment regimen bb2121-MM-001: bb2121 Registration-Enabling Trial (KarMMa) Endpoints Primary: ORR Key Secondary
Slide 14: Advancing bb2121 into Earlier Lines of Multiple Myeloma
Advancing bb2121 into Earlier Lines of Multiple Myeloma Registration-enabling trial in late line open to enrollment Planned Ph III in 3rd line vs. Dara/Pom/dex Explore label expansion opportunity in 2nd line setting Opportunities for bb2121 in NDMM including high risk, TNE and TE vs. transplant Comp
Slide 15: Closing
Closing Nick Leschly, chief bluebird
Slide 16: Response to Current Standard of Care in Late Line RRMM
Response to Current Standard of Care in Late Line RRMM Chari, A. Blood 2017 43
Slide 17: bb2121 Patient Case: Months in sCR
bb2121 Patient Case: 21 Months in sCR General Information Age & Gender 52 year old Male Dose group 150x10^6 Tumor Burden High High Risk Cytogenetics (based on FISH) No Number of prior regimens 6 Initial diagnosis May, 2010 BCMA% (prescreen, baseline) 60, 75 VRD, Doxo VRD, M, ASCT K Pom bb2121 Durati
Slide 18: Key Takeaways
Key Takeaways Efficacy? Durability? BCMA? MRD? Safety? Path forward? 95.5% ORR in doses above 150M cells. 50% CR rate at doses above 150M cells. 11.8 months median PFS in dose-escalation active doses. 17.7 months median PFS in MRD(-) patients with response (escalation and expansion). Consistent resp
Slide 19: Stay Tuned…
Stay Tuned… *Celgene Responsibility, **Anticipated Clinical Data Updates EHA MM Encore data presentation TDT Updated data SCD Updated data EHA Conference Call: June 15, 8:00 am ET 2H** TDT First clinical data in TDT and β0/β0 genotypes TDT EMA filing MM First bb21217 clinical data CALD Updated data
Slide 20: Q&A
Q&A bluebirdbio’